Striving to bring the best solution to reduce flare and tophi in gout patients

Learn More

 

About Us

Arthrosi Therapeutics is a clinical-stage biotech company focused on the development of therapy for gout and chronic kidney disease. Its proprietary drug candidate, AR882, demonstrated unprecedent sustained urate lowering in gout patients and showed potential to treat a variety of renal impaired patients suffering from gout and tophaceous gout..

Arthrosi strives to…

  • Create a people-centered environment — you are at the center of everything we do and every decision we make.
  • Be your partner in health — we work to bring a better quality of life to our patients.
Learn More

US gout patients

with flares

with tophi

chronic refractory gout patients

A large percentage of the 9 million patients living with gout are undertreated, relying on short-term or sub-optimal treatments that don’t meet their needs. Our mission is to eliminate the pain of gout with a new era of gout treatment that provides a true solution to reduce flare and tophi.

Litain Yeh

Co-Founder and CEO

Life at Arthrosi

Join our team if you share our values, our devotion to patients and our passion for science.